Alexandra M. Harrington, MD, MLS(ASCP)CM

Publications

• Primary Bone Lymphoma Masquerading as Multiple Myeloma: Challenges in the Diagnostic Workup of Severe Hypercalcemia.

  (Kahn E, Nomani L, Harrington AM, Asmi N.) Cureus. 2024 Jan;16(1):e51856 PMID: 38327974 PMCID: PMC10848882 02/08/2024

• Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.

  (Gorak EJ, Otterstatter M, Al Baghdadi T, Gillis N, Foran JM, Liu JJ, Bejar R, Gore SD, Kroft SH, Harrington A, Saber W, Starczynowski D, Rollison DE, Zhang L, Moscinski L, Wilson S, Thompson J, Borchert C, Sherman S, Hebert D, Walker ME, Padron E, DeZern AE, Sekeres MA.) Blood Adv. 2023 Oct 24;7(20):6120-6129 PMID: 37552083 PMCID: PMC10582385 SCOPUS ID: 2-s2.0-85175538659 08/08/2023

• Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.

  (DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ.) Blood Adv. 2023 Jul 25;7(14):3749-3759 PMID: 36947201 PMCID: PMC10368770 SCOPUS ID: 2-s2.0-85167336251 03/23/2023

• How I Diagnose Mature T-Cell Proliferations by Flow Cytometry.

  (Kroft SH, Harrington AM.) Am J Clin Pathol. 2022 Oct 06;158(4):456-471 PMID: 35929508 SCOPUS ID: 2-s2.0-85139572975 08/06/2022

• Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy.

  (Shah NN, Harrington AM.) Blood. 2022 Feb 17;139(7):1116 PMID: 35175320 SCOPUS ID: 2-s2.0-85124777621 02/18/2022

• Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome.

  (Corrao K, Rezwan S, Atallah E, Michaelis LC, Runaas L, Harrington AM, Abedin S.) Leuk Res Rep. 2022;17:100329 PMID: 35651540 PMCID: PMC9150024 SCOPUS ID: 2-s2.0-85131561638 06/03/2022

• Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse.

  (Dhakal B, Sharma S, Balcioglu M, Shchegrova S, Malhotra M, Zimmermann B, Billings PR, Harrington A, Sethi H, Aleshin A, Hari PN.) Front Oncol. 2022;12:786451 PMID: 35186734 PMCID: PMC8848740 SCOPUS ID: 2-s2.0-85124893548 02/22/2022

• Post-transplant primary cutaneous peripheral T-cell lymphoma not otherwise specified in a pediatric patient.

  (Cardwell LA, Majerowski J, Chiu YE, Harrington AM, Sokumbi O.) J Cutan Pathol. 2021 May;48(5):706-712 PMID: 33476057 SCOPUS ID: 2-s2.0-85102302501 01/22/2021

• Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.

  (Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS.) Leuk Lymphoma. 2021 Jan;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020

• Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them.

  (Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN.) Biol Blood Marrow Transplant. 2020 Jul;26(7):1288-1297 PMID: 32135202 SCOPUS ID: 2-s2.0-85083636589 03/07/2020

• Simple Laboratory Test Utilization Interventions to Reduce Inappropriate Specialty Coagulation Testing.

  (Huang H, Cunningham AM, Harrington AM.) Am J Clin Pathol. 2020 Jan 02;153(2):181-189 PMID: 31602457 SCOPUS ID: 2-s2.0-85077403173 10/12/2019

• Ancillary Studies in the Diagnostic Evaluation of Large B-Cell Lymphoma.

  (Cunningham AM, Harrington AM.) Arch Pathol Lab Med. 2019 Dec;143(12):1464-1471 PMID: 31584842 SCOPUS ID: 2-s2.0-85075813941 10/05/2019